Detalhe da pesquisa
1.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med
; 389(2): 148-157, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272527
2.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194692
3.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
N Engl J Med
; 386(7): 629-639, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904798
4.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34891224
5.
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Br J Haematol
; 204(4): 1293-1299, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38263627
6.
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.
Blood
; 139(10): 1452-1468, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724567
7.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica
; 109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731379
8.
EGFR as a potent CAR T target in triple negative breast cancer brain metastases.
Breast Cancer Res Treat
; 197(1): 57-69, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36318382
9.
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.
Blood
; 137(3): 420-428, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33475736
10.
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Blood
; 138(16): 1429-1440, 2021 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34157093
11.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica
; 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855036
12.
Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.
Eur J Haematol
; 110(6): 626-632, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36752328
13.
Poor hospitalization outcomes in patients undergoing allogeneic hematopoietic stem cell transplant with hospital acquired influenza infection.
Transpl Infect Dis
; 25(3): e14066, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129229
14.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 380(1): 45-56, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30501490
15.
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Cytotherapy
; 24(9): 869-878, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718701
16.
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination.
Eur J Haematol
; 109(5): 458-464, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810359
17.
Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
Transpl Infect Dis
; 24(2): e13792, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030267
18.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 22(10): 1403-1415, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34516954
19.
Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
BMC Cancer
; 21(1): 730, 2021 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172037
20.
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Eur J Haematol
; 107(6): 602-608, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378251